Evaluation of soluble fms-like thyroxine kinase-1 and endo-thelial antibodies in patients with acute coronary syndrome in the post-COVID period

Objective: to evaluate the role of soluble fms-like thyroxine kinase-1 and endothelial factor in patients with acute coronary syndrome in the post-COVID period. Material and methods. The study included 118 patients (including 57 women and 61 men) with acute coronary syndrome and COVID-19 history. Soluble fms-like thyroxine kinase-1 and endothelial factor were determined in all patients. The comparison group consisted of 121 patients with acute coronary syndrome without COVID-19. Results. High levels of soluble fms-like thyroxine kinase-1 and antibodies to endothe-lium were more often detected in the ACS and previous COVID-19 group than in the comparison group (risk ratio — RR=2.768 [95% confidence interval — Cl: 2.0810-3.681]; p<0.001) and (RR=1,554 [95% Cl: 1.216-1.987]; p=0.002), respectively. In the group of patients with ACS and COVID-19, a more severe course of ACS was also observed: rhythm disturbances were recorded more often (RR=1.372 [95% Cl: 1.005-1.784]; p=0.032), rehospitalization in the first 14 days for cardiovascular diseases (RR=1.475 [95% Cl: 1.100-1.977]; p=0.032) and hospital mortality (RR=1.610 [95% Cl: 1.160-2.233]; p=0.042). Conclusion. The obtained data allow us to say that anti-endothelial antibodies and soluble fms-like thyroxine kinase-1 are associated with the risk of developing severe ACS in patients with COVID-19 history.